68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer

Thomas Hope

Status and phase

Active, not recruiting

Phase 2

Conditions

Stage IV Prostate Cancer AJCC v8

Stage IVA Prostate Cancer AJCC v8

Castration-Resistant Prostate Carcinoma

Metastatic Prostate Carcinoma

Stage IVB Prostate Cancer AJCC v8

Treatments

Drug: 68Ga-PSMA-11

Procedure: Positron Emission Tomography (PET)

Study type

Interventional

Funder types

Other

Identifiers

NCT04716725

NCI-2020-13741 (Registry Identifier)

209211

Details and patient eligibility

About

This phase II trial studies the use of 68Ga-PSMA-11 positron emission tomography (PET) in diagnosing patients with prostate cancer that continues to grow despite the surgical removal of the testes or medical intervention to block androgen production (castration resistant), and has spread to other places in the body (metastatic). 68Ga- PSMA-11 is a new imaging agent that may help get more detailed pictures of the tumor. This trial aims to see whether using 68Ga-PSMA-11 PET scans may help doctors learn more about where disease is located in the body.

Full description

PRIMARY OBJECTIVE:

I. To determine whether the percent change from baseline to 16 weeks (+/- 8 weeks) in maximum standard uptake value (SUVmax) averaged across up to 16 lesions per patient (SUVmax-ave) is associated with >= 50% decline from baseline in serum prostate specific antigen (PSA50) response.

SECONDARY OBJECTIVES:

I. To determine whether the percent change from baseline in SUVmax-ave on PSMA PET is associated with time-to-event endpoints including PSA progression-free survival and overall survival.

II. To determine whether the percent change from baseline in SUVmax on PSMA PET is associated with objective response by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 on a per-lesion basis among measurable soft tissue lesions present at baseline.

EXPLORATORY (CORRELATIVE) OBJECTIVES:

I. To descriptively characterize the histologic, transcriptional, and genomic features of PSMA low/negative lesions among patients who undergo paired optional metastatic tumor biopsy.

II. To descriptively characterize the relationship between SUVmax-ave on baseline Ga-PSMA PET with optional baseline fludeoxyglucose F-18 (FDG)-PET.

III. To determine whether heterogeneity of PSMA expression on baseline Ga-PSMA PET is associated with overall survival.

IV. To descriptively characterize the patterns of PSMA expression at the time of disease progression among patients who undergo optional PSMA PET.

V. To determine whether the percent change from baseline in PSMA PET is associated with PSA50 response among subgroups of patients defined by treatment modality received, including androgen receptor (AR) targeting treatment, PSMA-targeting radioligand therapy, cytotoxic chemotherapy, and immunotherapy.

OUTLINE:

Patients receive gallium Ga 68-PSMA-11 intravenously (IV) and undergo PET at baseline, 16 weeks after initiating therapy, and at time of disease progression.

After progression or study completion, patients are followed up every 3 months for up to 24 months

Enrollment

15 patients

Sex

Male

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Sub-cohort A1: Patients must have baseline evaluations performed within 12 weeks prior to the start of systemic therapy.
Sub-cohort A2: Patients must meet all the following requirements:
- Have had a baseline pre-treatment 68Ga-PSMA-11 PET scan and PSA measurement performed within 12 weeks prior to the start of current systemic therapy.
- Able to have an on-treatment 68Ga-PSMA-11 PET and a PSA measurement within 16 weeks (+/- 8 weeks) after the start of current systemic therapy.
Note: The screening period for sub-cohort A2 is within 24 weeks after the patient started their current systemic therapy.
Patients must have progressive castration resistant prostate cancer, according to PCWG3 criteria.
Patients must have planned initiation of systemic treatment (sub-cohort A1), or ongoing systemic treatment (sub-cohort A2) for castration resistant prostate cancer within 12 weeks of baseline Ga-PSMA PET.
Patients must have at least one metastatic lesion with PSMA uptake at or above the blood pool on their baseline PSMA PET scan.
The patient must be able and willing to comply with study procedures and provide signed and dated informed consent.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Patient must be Aged 18 years or older at the time of study entry.
Patients who undergo optional metastatic tumor biopsy following completion of baseline Ga-PSMA PET must additionally meet all of the following criteria:
- Presence of one or more metastases by standard radiographic scans that is safely accessible to tumor biopsy in the judgment of treating clinician and/or Interventional Radiology.
- No history of radiation therapy to the target metastatic lesion selected for tumor biopsy.
- No contra-indication to biopsy including uncontrolled bleeding diathesis.
- Platelets > 75,000/ul and prothrombin time (PT) or institution normalized ratio (INR) and a partial thromboplastin time (PTT) < 1.5 times the institutional upper limit of normal (ULN) within 14 days prior to biopsy.

Exclusion criteria

Patients who because of age, general medical or psychiatric condition, or physiologic status cannot give valid informed consent.
Patients with any condition that, in the opinion of the Principal Investigator, would impair the patient's ability to comply with study procedures.
Patients with any contra-indication to magnetic resonance imaging (MRI) (e.g. pacemaker placement, severe claustrophobia) Note: The exclusion criteria above (3) is only applicable for patients scheduled for a Positron Emission Tomography (PET) MRI (PET/MRI).